A Phase 3 interventional study of rituximab and Dexamethasone in Idiopathic Thrombocytopenic Purpura, sponsored by Hoffmann-La Roche. Completed at 22 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-22.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. Rituximab · Purpura, Thrombocytopenic, Idiopathic.
Among the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, this one is the 9th largest by enrollment, is the only one that started in 2005, is one of 8 in phase 3, and was the 9th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic are open now, in 4 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
New York Medical College · Sites in United States
Ages 1–21
Nahda University · Sites in Egypt
Ages 18–65
Ostfold Hospital Trust
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 10 · Phase 4 2
First in 2000; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 60 across the 27 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
1 of the studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10\^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m\^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
Drug: Dexamethasone
Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (\<) 20 x10\^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
Drug: rituximab · Drug: Dexamethasone
Also known as: MabThera/Rituxan
Percentage of Participants With a Sustained Response
Sustained response defined as a platelet count of greater than or equal to (≥) 50x10\^9/L at 6 months (Week 24) after the initial treatment. Participants failing therapy before Month 6 (Week 24) and treated in other ways were considered failures.
Time frame: Week 24
Percentage of Participants With an Initial Response
Initial response was defined as an increase in platelet count of ≥50x10\^9/L by Day 30 (Week 4) after the start of treatment in either treatment arm.
Time frame: Week 4
Percentage of Participants With an Initial Complete Response
Initial complete response was defined as an increase in platelet count of ≥100x10\^9/L by Day 30 (Week 4) after the initiation of treatment in either treatment arm.
Time frame: Week 4
| Milestone | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab |
|---|---|---|
| Started | 53 | 50 |
| Completed | 52 | 49 |
| Not completed | 1 | 1 |
| Withdrew: Did not take treatment | 1 | 1 |
Sustained response defined as a platelet count of greater than or equal to (≥) 50x10\^9/L at 6 months (Week 24) after the initial treatment. Participants failing therapy before Month 6 (Week 24) and treated in other ways were considered failures.
| percentage of participants | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab |
|---|---|---|
| Percentage of Participants With a Sustained Response | 36 | 63 |
Initial response was defined as an increase in platelet count of ≥50x10\^9/L by Day 30 (Week 4) after the start of treatment in either treatment arm.
| percentage of participants | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab |
|---|---|---|
| Percentage of Participants With an Initial Response | 27 | 68 |
Initial complete response was defined as an increase in platelet count of ≥100x10\^9/L by Day 30 (Week 4) after the initiation of treatment in either treatment arm.
| percentage of participants | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab |
|---|---|---|
| Percentage of Participants With an Initial Complete Response | 23 | 48 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Dexamethasone | — | 1/52 (1.9%) | 25/52 (48.1%) |
| Arm B: Dexamethasone + Rituximab | — | 3/49 (6.1%) | 37/49 (75.5%) |
| Salvage Therapy | — | 3/27 (11.1%) | 18/27 (66.7%) |
| Event | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab | Salvage Therapy |
|---|---|---|---|
| Platelet count decreasedBlood and lymphatic system disorders | 0/52 | 0/49 | 1/27 |
| ConvulsionNervous system disorders | 0/52 | 0/49 | 1/27 |
| SeizureNervous system disorders | 0/52 | 0/49 | 1/27 |
| TIANervous system disorders | 0/52 | 0/49 | 1/27 |
| Hemorrhagic syndrome and low plateletBlood and lymphatic system disorders | 0/52 | 0/49 | 1/27 |
| Hemorrhage syndromeBlood and lymphatic system disorders | 0/52 | 1/49 | 0/27 |
| Supraventricular tachycardiaCardiac disorders | 0/52 | 1/49 | 0/27 |
| Interstitial pneumoniaInfections and infestations | 0/52 | 1/49 | 0/27 |
| Rib fractureInjury, poisoning and procedural complications | 1/52 | 0/49 | 0/27 |
| Event | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab | Salvage Therapy |
|---|---|---|---|
| PyrexiaGeneral disorders | 1/52 | 10/49 | 5/27 |
| Abdominal pain upperGastrointestinal disorders | 1/52 | 7/49 | 2/27 |
| HeadacheNervous system disorders | 3/52 | 6/49 | 2/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/52 | 6/49 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 0/52 | 5/49 | 0/27 |
| AstheniaGeneral disorders | 2/52 | 5/49 | 0/27 |
| NasopharyngitisInfections and infestations | 2/52 | 4/49 | 0/27 |
| PetechiaeSkin and subcutaneous tissue disorders | 4/52 | 0/49 | 1/27 |
| LeukopeniaBlood and lymphatic system disorders | 0/52 | 0/49 | 2/27 |
| ConstipationGastrointestinal disorders | 1/52 | 1/49 | 2/27 |
| Age, Continuous(years) | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab | Total |
|---|---|---|---|
| Mean | 47 ± 19 | 49 ± 16 | 48.41 ± 18.03 |
| Sex: Female, Male(Participants) | Arm A: Dexamethasone | Arm B: Dexamethasone + Rituximab | Total |
|---|---|---|---|
| Female | 33 | 27 | 60 |
| Male | 19 | 22 | 41 |
The record gives a start of Jul 2005, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Purpura, Thrombocytopenic, Idiopathic →